Execitalopram oxalate tablets, a new Kangenbei 3.1 drug, has been approved for production

According to the latest information on the website of the State Food and drug administration, Kangenbei 3.1 new drug, escitalopram oxalate, has been approved for production The drug is a first-line antidepressant widely used in the world, with a total sales volume of more than 100 million yuan in China last year Kangenbei's approved production of new spiritual drugs can enrich the company's existing product line and play a positive role in future performance Kangenbei is one of the leading enterprises of modern Chinese medicine It has established a complete product echelon and brand advantages in the two fields of cardiovascular and cerebrovascular system medicine and urinary system medicine At the same time, it has brand-name products and strong market competitiveness in the fields of digestion, anti infection and other disease treatment The sales of seven varieties, including QianLieKang and Changyanning, exceed 100 million This year, many varieties of the company were selected into the national base drug catalog and local supplement catalog, among which Tianbaoning ginkgo leaf capsule, omeprazole injection, tamoxin sustained-release capsule were selected into the national new base drug catalog, shexiangtongxin dropping pills were added into the base drug catalog of Guangdong Province and the new agricultural cooperation catalog of Fujian Province, and yanyanning was selected into the supplement base drug catalog of Qinghai Province The company's net profit in the first three quarters of this year increased by 70% year on year